지연유합과 불유합에서 저신호 강도 초음파의 유용성

윤여헌,김종오,고영도,유재두,정준모,오종건,방한천,최창호,신명철 대한골절학회 2003 대한골절학회지 Vol.16 No.1

목 적 : 저 신호 강도 초음파를 이용한 지연유합과 불유합의 치료에 대한 유용성을 알아보고자 하였다. 대상 및 방법 : 2001년 7월부터 2002년 5월까지 본원에 내원한 지연유합 7례와 불유합 8례를 대상으로 5개월간 저 신호 강도 초음파로 치료하여 5개월후 골유합 여부를 알아 보았다. 결 과 : 총 15례 중 대퇴골 간부 2례, 경골 간부 1례, 상완골 간부 1례, 요골 1례의 지연유합에서 골유합을 얻었고 대퇴골 간부 불유합 3례에서 유합을 얻었다. 지연주합은 71%의 유합율을, 불유합은 37.5%의 유합율을 보였다. 결 론 : 저 신호 강도 초음파는 골유합을 촉진 시킬 수 있으며 지연유합에서 시도해 볼 만 하나 불유합 치료를 위해서는 보다 많은 연구가 필요 하다. Purpose : To evaluation of usefulness of low-intensity ultrasound for nonunion and delayed union. Materials and Methods : For 5 months, we treated 7 delayed union and 8 nonunion using low-intensity ultrasound. After 5 months, in checked X-ray AP and Lateral view, when cortical bridge formation was done, we through union. Results : In 7 delayed union, 5 cases-2 femur, tibia, humerus, radius were healed. In 8 nonunion, 3 femur nonunion were healed. Union rate was 71% in delayed union 37.5% in nonunion. Conclusion : we thought that the low-intensity ultrasound has capacity of induction of union and was considered as the method of treatment for delayed union.

노령의 대퇴 전자간 골절 치료에서 압박고 나사못의 안정성 및 유용성

김종오,노권재,윤여헌,고영도,유재두,정준모,방한천,정재학 대한골절학회 2003 대한골절학회지 Vol.16 No.2

목 적: 노령의 대퇴 전자간 골절에서 압박고 나사못의 안정성에 영향을 주는 인자들간의 상관 관계와 골절 양상에 따른 술후 고관절 기능을 평가 및 분석하였다. 대상 및 방법: 압박고 나사를 이용하여 수술적 치료를 시행한 231명의 환자 중 6개월 이상 추시가 가능하였던 60세 이상 84명의 환자들을 대상으로 했다. 방사선적 계측은 압박고 나사못의 활강 길이 및 내반각, 가압 나사 위치, 정복 상태, 원위 골편의 내측 전위를 측정하였으며 술후 기능은 Clawson의 기능 평가표로 하였고 골절 양상에 따라 방사선 계측과 기능 회복과의 상관 관계를 평가하였다. 결 과: 임상 결과는 불안정 골절에서 양호가 10례, 불량이 23례, 안정 골절에서는 양호 40례, 불량이 11례로 안정 골절에서 임상 결과가 좋았고(p<0.001), 압박고 나사 활강은 10 ㎜ 이상일 때 양호가 4례, 불량이 21례, 10 ㎜ 이하에서 양호가 46례, 불량이 13례로 10 ㎜ 이상 활강시에 술후 결과가 불량했다(p<0.001). 다르 방사선적 계측 요인은 결과에 의미있는 차이를 보이지 않았다. 또한, 불안정 골절 중에서 전위 양상 골절의 경우 10㎜ 이상 활강이 12례, 10㎜ 이하 활강이 8례, 분쇄 양상 골절의 경우는 10㎜ 이상이 11례, 10㎜ 이하가 2례로 분쇄 양상의 불안정 골절에서 10㎜ 이상 활강이 의미있게 많았다 (p<0.001). 결 론: 10㎜ 이상의 지연 나사 활강은 고관절 기능 회복 약화를 유발시킬 수 있으며 불안정 골절 분쇄 양상 골절은 이런 지연 나사의 활강이 과도하게 유발될 수 있으므로 불안정 분쇄 양상 골절에서 압박고 나사의 단독 사용은 재고해 보아야 할 것이다. Purpose: To evaluate the relationship between fracture stability and functional results, and analyze the correlation between stability factors and the outcome in intertrochanteric fracture of the elderly. Materials and Methods: Of the 231 patients, 84 patients with age above 60 were able to follow up for minimum 6 months. We measured the sliding length of the lag screw, varus degree, position of lag screw, reduction status and medialization of distal fragment radiologically. The functional outcome of the treatment was evaluated with the Clawson's result classification and we evaluated the correlation between the radiological results of measurement and the functional recovery depending on the Evans fracture classification. Results: There were good results in 40 cases out of 51 stable fractures, and in 10 cases out of 33 unstable fractures (p<0.001). In case of sliding of lag screw more than 10㎜, good results were obtained in 4 cases, and poor in 21. And in case of sliding less than 10㎜, good results were obtained in 46, and poor in 13. (p<0.001).But there was no relationship between other radiologic factors and clinical results. In unstable type, there were 12 cases with lag screw sliding more than 10㎜ and 10 cases with less than 10㎜. In comminuted type, there were 11 cases with lag screw sliding more than 10㎜ and 2 cases with less than 10㎜(p<0.001). Conclusion: The sliding of lag screw more than 10㎜ may result in poor outcome. As in comminuted unstable pattern, sliding of lag screw might be excessive, the use of compression hip screw alone is not good treatment option.

Staphylococcus aureus와 Coagulase-Negative Staphylococcus Species에 대한 Arbekacin의 시험관내 항균력

위성헌,강진한,허동호,이동건,김상일,김양리,최정현,김종현,유진흥,허재균,신완식,강문원 대한감염학회 2001 감염 Vol.33 No.4

Background : Most strains of methicillin-resistant Staphylococcus aureus (MRSA) now exhibit high-level resistance to various antibiotics, such as β -lactam antibiotics, aminoglycosides, macrolides, tetracyclines and quinolones. Recent reports describing the therapeutic failure of vancomycin for MRSA infections have arisen considerable concerns regarding the emergence of MRSA strains, which will require new therapeutic agents. Arbekacin, an aminoglycoside antibiotic, has antibacterial activity against both gram-positive and gram-negative bacteria and is stable in the presence of aminoglycoside inactivating enzymes produced by S. aureus. In this study, we compared the antibacterial activity of arbekacin with those of vancomycin, gentamicin, and amikacin against Staphylococcus aureus (S. aureus) and coagulase-negative staphylococci (CNS). Methods : For a collection of 549 S. aureus and 251 CNS isolates from three Catholic University Hospitals in Korea, minimum inhibitory concentrations (MICs) of arbekacin, vancomycin, amikacin and gentamicin were determined by agar dilution method using Mueller-Hinton agar according to NCCLS (National Committee for Clinical Laboratory Standards, USA)criteria. Results : Among 549 S. aureus isolates, 278 isolates were MRSA and 271 isolates were methicil sensitive S. aureus (MSSA). MIC50 & MIC90 of arbekacin against 549 S. aureus were 0.5 & 1 ㎍/mL, and MIC50 & MIC90 of vancomycin were 1 & 1 ㎍/mL. MIC of arbekacin against 549 S. aureus isolates ranges from 0.03 to 4 ㎍/mL, and MIC of vancomycin against 549 S. aureus ranges from 0.25 to 2 ㎍/mL. MIC90 of amikacin against 549 S. aureus was 32㎍/mL, and that of gentamicin was 128 ㎍/mL. MICs of amikacin and gentamicin were variable, ranging from 0.125 to 256, and otherwise arbekacin and vancomycin revealed relatively narrow range of MICs. MIC90 of arbekacin against 278 MRSA isolates & 271 MSSA were 1 & 0.5 ㎍/mL, and those of vancomycin against MRSA & MSSA were 1 & 1 ㎍/mL. MIC90 of amikacin against 278 MRSA & 271 MSSA isolates were 32 & 4 ㎍/mL, and that of gentamicin against MRSA & MSSA isolates were 128 & 32 ㎍/mL respectively. Among 251 CNS isolates, 122 isolates were MRCNS and 129 were MSCNS. MICSO & MIC90 of arbekacin against 251 CNS isolates were 0.25 & 2 ㎍/mL, and those of vancomycin were 1 & 2 ㎍/mL. MIC of arbekacin against 251 CNS isolates ranges from 0.015 to 32 ㎍/mL, and that of vancomycin isolates ranges from 0.25 to 2 ㎍/mL, MIC90 of arbekacin against 122 MRCNS & 129 MSCNS isolates were 2&0.3 ㎍/ML, and those of vancomycin were 2&s ㎍/ML. MIC90 of amikacin against 251 CNS isolates was 32 ㎍/ML, and that of gentamicin was 128 ㎍/ML for CNS. MIC90 of amikacin against 122 MRCNS & 129 MSCNS isolates were 128 & 8㎍/mL, and those of gentamicin ere 256 & 32 ㎍/mL. Conclusion : Considering above results, arbekacin can be useful agent against most strains of MRSA and MRCMS, which exhibit high-level resistance to amikacin and gentamicin. (Korea J Infect Dis 33:254~260, 2001)

월경주기 증상의 요인 분석

이수일,유태혁,강종선,안석철,이병욱,김헌,석재호 大韓神經精神醫學會 1986 신경정신의학 Vol.25 No.1

404 nurses and nurse-aids rated their experiences of 45 symptoms(Moos' Menstrual Distress Questionnaire) of the menstrual, premenstrual and intermenstrual phase on a 4 point scale separately. The 45 symptoms were inter-related and factor analyzed separately for each phase. six common clusters of symptoms emerged from 3 phases, which were labeled concentration, motor tension, pain, pleasurable affect, autonomic reactions and water retention. Four clusters of symptoms emerged from premenstrual phase. These clusters were labeled instabillity, withdrwal reactions, depression and headache. The factor named unpleasurable affect emerged from intermenstrual and menstrual phase. Above findings were differed from the results of Moos' study in which eight basically replicated clusters of symptoms emerged from three phases. Through discussion of validity of this scale, and differences between results of Moos' and this study, we came to the conclusion that sampling of subjects, prospective longitudinal symptoms reporting, amount of variance in a symptom over the course of menstrual cycle and proper choice of factor analysis method would be salient variables to construct valid scale for measuring menstrual cycle symptoms.

GG-19 : Association between the uterine volume and efficacy in patients with adenomyosis treated with levonorgestrel-releasing intrauterine device

( Heon Jong Yoo ),( Jang Kew Kim ),( Byung Hun Kang ),( Jung Bo Yang ),( Young Bok Ko ),( Min A Lee ),( Ki Hwan Lee ) 대한산부인과학회 2012 대한산부인과학회 학술대회 Vol.99 No.-

The objective of this study is to evaluate the relationship between the uterine volume and the effects of levonorgestrel-releasing intrauterine device (LNG-IUD) treatment in patients with adenomyosis A total of 171 women with adenomysis were treated with LNG-IUD between November 2009 and December 2011. The amount of menorrhagia, degree of dysmenorrhea, uterine volume before and after insertion of LNG-IUD, and treatment failure of LNG-IUD were observed. The mean uterine volume of patients with adenomyosis which was treated by LNG-IUD was 158 mL (range, 46-769 mL). Visual analog pain scales, pictorial blood assessment chart scores and mean uterine volume were decreased after insertion of LNG-IUD significantly in 6 months (p=0.001, p=0.005, and p=0.005, respectively). There was significant difference of uterine volume between treatment failure group and success group (178 mL and 141mL p=0.010). Based on receiver operator characteristic curve analysis, optimum cutoff value of uterine volume more than 150 mL was significantly associated with failure of treatment after LNG-IUD insertion (area under receiver operator characteristic curve: 0.763, 95% confidence interval [CI]: 0.669-0.856). In univariate analysis, uterine volume more than 150 mL was the only independent factor for treatment failure after insertion of LNG-IUD (odds ratio 6.76, 95% CI: 1.20-38.02, p=0.030). The LNG-IUD might be an effective expectant management for patients with adenomyosis. However, the patients who have uterine volume more than 150 mL is recommended to avoid the insertion of LNG-IUD in adenomyosis.

Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.

Yoo, Heon Jong,Lim, Myong Cheol,Lim, Soyi,Park, Jeong-Yeol,Kang, Sokbom,Park, Sang-Yoon,Seo, Sang-Soo Springer International 2012 Archives of gynecology and obstetrics Vol.286 No.6

<P>To evaluate the efficacy and toxicity of combined paclitaxel and carboplatin treatment for persistent or recurrent uterine sarcoma.</P>

Laparotomy staging of Early Endometrial Cancer

( Heon Jong Yoo ),( Jong Ha Hwang ),( Sang Soo Seo ),( Sokbom Kang ),( Myong Cheol Lim ),( Sang Yoon Park ) 대한산부인과학회 2011 대한산부인과학회 학술대회 Vol.97 No.-

Correlation Between Body Mass Index and Prevalence of Hereditary Nonpolyposis Colorectal Cancer in Korean Patients With Endometrial Cancer :

Yoo, Heon Jong,Joo, Jungnam,Seo, Sang-Soo,Kang, Sokbom,Yoo, Chong Woo,Park, Sang-Yoon,Lim, Myong Cheol BMJ 2012 International journal of gynecological cancer Vol.22 No.2

<P>The purpose of the study was to investigate the relationship between body mass index (BMI) and hereditary nonpolyposis colorectal cancer (HNPCC) in Korean women with endometrial cancer.</P>

The development of the waypoint following logic using pure pursuit via ROS publish and subscribe system

Yoo Heon Jong,Choi Won Seok,Choi Seong Gon 한국통신학회 2024 한국통신학회 학술대회논문집 Vol.2024 No.1

The critical pathway for cytoreductive surgery with bowel resection and anastomosis on ovarian cancer

( Heon Jong Yoo ),( Myong Cheol Lim ),( Sokbom Kang ),( Sang Soo Seo ),( Sang Yoon Park ) 대한산부인과학회 2012 대한산부인과학회 학술대회 Vol.98 No.-

The aim of this study was to investigate the safety, feasibility, and economic impact of a clinical pathway for ovarian cancer, the critical pathway which encompasses cytoreductive surgery with bowel resection and anastomosis. Forty five patients who had cytoreductive surgery with bowel resection and anastomosis were studied. The patients` demographics at the time of their cytoreductive surgery were screened retrospectively. Twenty out of 45 ovarian cancer patients (44.4%) were assigned to the critical pathway group. This 20 patients consisted of 6 early (stage I or II), 9 advanced (stage III or IV), and 5 recurrent ovarian cancer patients (30.0%, 45% and 25%, respectively). There was no significant difference in the mean age, preoperative serum albumin, CA125, diabetes, and hypertension between the two groups with and without the critical pathway. Surgical procedure, completeness of optimal cytoreductive surgery, operation time, estimated blood loss, intraoperative transfusion, and the mean length of ICU stays did not differ between the two groups as well. However, there was a definite difference in the postoperative days until the beginning of oral diet, the removal of nasogastric tube, and flatus (5.8 vs. 7.7, 0.5 vs. 1.3, and 4.2 days vs. 5.2 days, respectively). Morbidity, total hospital stays, and total costs were not significantly different (32% vs. 35%, 23.6 days vs. 26.3 days, and $11,785 vs. $11,898, respectively). The critical pathway for primary cytoreductive surgery with bowel surgery in ovarian cancer patients appears to be feasible and safe. However, the critical pathway does not significantly reduce the length of stay at hospitals and hospital-related costs. These results should be verified further by future studies that incorporate a large-scale, randomized, multi-institutional, and collaborative investigation.